<DOC>
	<DOCNO>NCT01447069</DOCNO>
	<brief_summary>The purpose study determine whether Salbutamol effective treatment severe heart failure due ischemic non- ischemic cardiomyopathy .</brief_summary>
	<brief_title>Use Beta-agonists Stable Severe Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Ambulatory Patients diagnosis ischemic nonischemic cardiomyopathy measure EF &lt; 35 % , class III define NYHA ICD receive optimal pharmacological therapy . Heart Failure class I , II , IV atrial fibrillation significant valvular disease chronic obstructive pulmonary disease treat inhaled Î²2 agonist significant kidney disease eGFR &lt; 30 % severe uncontrolled electrolyte abnormality prior allergic reaction Salbutamol Pregnancy nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>heart failure stage 3</keyword>
	<keyword>beta 2 agonist</keyword>
	<keyword>N-terminal pro-brain natriuretic peptide</keyword>
	<keyword>ejection fraction &lt; 35 %</keyword>
</DOC>